Condition: Androgen Deprivation Therapy · Locally Advanced Prostate Cancer · Sponsor: University of Oklahoma
The goal of this clinical trial is to test how effective and safe it is to use a combination of two medications, relugolix and enzalutamide, in patients with advanced prostate cancer. We want to see if this combination can help improve the chances of curing the cancer and make the patients live longer without the cancer getting worse. The main questions we want to answer in this study are: * Can using relugolix and enzalutamide together help increase the chances of curing high-risk advanced prostate cancer? * Does this combination treatment help patients live longer without their cancer getting worse? Participants in this study will be asked to take relugolix and enzalutamide as part of their cancer treatment. They will also undergo Radiation Therapy or prostatectomy, which are standard treatments for this type of cancer.
This description comes directly from the study's public registry record.
lead onco nurse, RN · 405-271-8777 · SCCIITOffice@ouhsc.edu
Kelly Stratton, MD · (405) 271-6900 · Kelly-Stratton@ouhsc.edu
Always discuss trial participation with your own doctor first.
| Stephenson Cancer Center at OU Health, University of Oklahoma Health Sciences Center (SCC-OUHSC) | Oklahoma City, Oklahoma, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06130995